Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials. - Venkatraman N; Tiono AB; Bowyer G; Bellamy DG; Stockdale LK; Powlson J; Collins KA; Coulibaly S; Datoo MS; Silman D; Ouedraogo A; Nébié I; et al. (The Lancet. Microbe, 2025)